Related Experiment Video

Updated: Oct 9, 2026

A New Single Chamber Implantable Defibrillator with Atrial Sensing: A Practical Demonstration of Sensing and Ease of Implantation
16:40

A New Single Chamber Implantable Defibrillator with Atrial Sensing: A Practical Demonstration of Sensing and Ease of Implantation

Published on: February 28, 2012

Preventing sudden death in coronary cardiomyopathy: implantable defibrillators lead the way

S Pavia1, B L Wilkoff

  • 1Department of Cardiology, Cleveland Clinic Foundation, OH 44195, USA.

Cleveland Clinic Journal of Medicine
|February 28, 2001
PubMed

Insights

Electrophysiology testing-guided therapy, including defibrillator implantation, significantly lowers sudden cardiac death risk in high-risk coronary artery disease patients. All eligible patients should undergo testing and consider defibrillator implantation if indicated.

Area of Science:

  • Cardiology
  • Electrophysiology
  • Clinical Trials

Background:

  • Coronary artery disease (CAD) with reduced ejection fraction and ventricular arrhythmias poses a high risk of sudden cardiac death.
  • Nonsustained ventricular tachycardia (NSVT) in this population requires risk stratification.
  • Electrophysiology (EP) testing is a key tool for assessing arrhythmia inducibility.

Purpose of the Study:

  • To evaluate the efficacy of EP testing-guided therapy in reducing mortality and cardiac arrest in high-risk CAD patients.
  • To determine if implantable defibrillator (ICD) therapy is essential for risk reduction in this cohort.

Main Methods:

  • The Multicenter Unsustained Tachycardia Trial (MUSTT) enrolled patients with CAD, LVEF ≤40%, and NSVT.
  • Patients underwent EP testing to assess ventricular arrhythmia inducibility.
  • Therapeutic strategies were guided by EP testing results, including ICD implantation.

Main Results:

  • EP-guided therapy significantly reduced the risk of arrhythmic death and cardiac arrest.
  • This benefit was primarily observed in patients who received an implantable defibrillator based on EP testing results.
  • Patients with inducible ventricular arrhythmias on EP testing showed a marked benefit from ICD implantation.

Conclusions:

  • EP testing is crucial for identifying patients with CAD, reduced LVEF, and NSVT who are at high risk for sudden cardiac death.
  • Implantable defibrillator therapy guided by EP testing is highly effective in preventing arrhythmic events in this patient group.
  • Routine EP testing and consideration of ICD implantation are recommended for all patients meeting MUSTT criteria.

More Related Videos

Porcine Cardiac Arrest Model Using an Implantable Defibrillator08:33

Porcine Cardiac Arrest Model Using an Implantable Defibrillator

Published on: January 9, 2026

Testing the Efficacy of Pharmacological Agents in a Pericardial Target Delivery Model in the Swine10:05

Testing the Efficacy of Pharmacological Agents in a Pericardial Target Delivery Model in the Swine

Published on: July 7, 2016

Related Concept Videos

Cardiomyopathy V: Interprofessional Care01:29

Cardiomyopathy V: Interprofessional Care

Managing cardiomyopathy involves addressing underlying or precipitating causes, treating heart failure with medications, and implementing dietary changes and a balanced exercise and rest regimen.Lifestyle ModificationsCardiomyopathy patients should adopt a low-sodium diet to reduce fluid retention and manage heart failure. A personalized exercise and rest plan helps maintain physical fitness without overstraining the heart. Avoiding alcohol and tobacco is essential to prevent further damage to...
Cardiomyopathy II: Dilated Cardiomyopathy01:30

Cardiomyopathy II: Dilated Cardiomyopathy

Dilated cardiomyopathy, or DCM, is a progressive myocardial disorder characterized by ventricular chamber dilation and contractile dysfunction.EtiologyVarious factors can cause DCM, including hypertension and heavy alcohol intake, which contribute to the weakening and enlargement of the heart muscle. Viral infections, such as Coxsackievirus B, adenoviruses, and influenza, can lead to DCM by causing inflammation and damage to heart tissue. Certain chemotherapeutic agents, including daunorubicin,...
Cardiopulmonary Resuscitation III: AED Use01:23

Cardiopulmonary Resuscitation III: AED Use

Introduction to AEDAn Automated External Defibrillator (AED) is a portable medical device that analyzes the heart's rhythm and, if necessary, delivers an electrical shock to help the heart re-establish an effective rhythm during sudden cardiac arrest (SCA). SCA occurs when the heart suddenly and unexpectedly stops beating, leading to a loss of blood flow to the brain and other vital organs. In such emergencies, time is of the essence, and using an AED, combined with Cardiopulmonary...
Dysrhythmias VI: Management of Dysrhythmias01:25

Dysrhythmias VI: Management of Dysrhythmias

Dysrhythmia management involves a multifaceted approach, incorporating pharmacological treatments, medical procedures, surgical interventions, lifestyle modifications, and patient education.Pharmacological ManagementAntiarrhythmic Drugs:Class I (Sodium Channel Blockers): This class includes quinidine and procainamide, which reduce the speed of impulse conduction in the heart, stabilize the cardiac membrane, and control arrhythmias. Quinidine and procainamide are Class IA agents that prolong the...
Cardiomyopathy III: Hypertrophic Cardiomyopathy01:29

Cardiomyopathy III: Hypertrophic Cardiomyopathy

Hypertrophic cardiomyopathy, or HCM, is an autosomal dominant genetic disorder characterized by asymmetric left ventricular hypertrophy without ventricular dilation. It is more common in men and is typically diagnosed in young, athletic adults.EtiologyHCM is primarily genetic and is caused by mutations in genes encoding sarcomeric proteins. Researchers have identified over 1400 mutations across at least 11 different genes. Among these, the most frequently occurring mutations are found in the...
Coronary Artery Disease IV: Preventive Measures01:26

Coronary Artery Disease IV: Preventive Measures

Effective preventive measures for coronary artery disease (CAD) focus on controlling modifiable risk factors, including cholesterol abnormalities and lifestyle changes.Cholesterol ManagementFirst, the Mediterranean diet and the American Heart Association advocate for maintaining low-density lipoprotein (LDL) cholesterol levels below 100 mg/dL, with a more stringent recommendation of below 70 mg/dL for individuals at high risk. LDL cholesterol, often termed "bad cholesterol," can lead to the...